Articles by Greg Malzberg, MD

ADHD_Course_Graphic.png

Audio Course - Adult ADHD: Comprehensive Diagnosis and Treatment

Commuter Audio Course
March 22, 2025
Greg Malzberg, MD

Gregory Malzberg, MD. Attending Psychiatrist & Assistant Clinical Professor, Mount Sinai West, New York, NY. Creator, PsychoFarm.

Lawrence H. Diller, MD Private Practice, Behavioral Pediatrics, Walnut Creek, California Clinical Faculty, UCSF School of Medicine Author, The Last Normal Child, Running on Ritalin and Should I Medicate My Child?

Doctors Malzberg and Diller have disclosed that they have no significant relationships with or financial interests in any commercial companies pertaining to this educational activity.

Welcome to our course on treating ADHD in adults. Throughout these modules, we will dive into the latest approaches to understanding, diagnosing, and managing ADHD in adult patients. Whether you're refining your skills or building a foundation, this course is designed to provide practical, evidence-based strategies that you can apply in your practice.


Read More
Adult_ADHD_sm.png
Clinical Update

How to Select a Stimulant for Adult ADHD

March 1, 2025
Greg Malzberg, MD

Gregory Malzberg, MD. Attending Psychiatrist & Assistant Clinical Professor, Mount Sinai West, New York, NY. Creator, PsychoFarm.

Dr. Malzberg has no financial relationships with companies related to this material.

We have 30 stimulant formulations, but do all deserve prizes? We find a few with niche advantages, and three that rise to the top.



Read More
Alpha2Thumb.png

KarXT (Cobenfy): The Breakthrough Antipsychotic That Could Change Everything

October 18, 2024
Jason Mallo, DO and Greg Malzberg, MD
In this video, we take an in-depth look at the recently FDA-approved antipsychotic, KarXT, also known by its brand name Cobenfy. This new drug represents a major breakthrough in schizophrenia treatment because, unlike traditional antipsychotics, it doesn’t rely on blocking dopamine receptors. Instead, KarXT works through a muscarinic agonist mechanism, making it a completely different approach to managing schizophrenia and other psychotic disorders.
Read More
Alpha2Thumb.png

Alpha-2 Agonists Review: Clonidine (Kapvay) and Guanfacine (Intuniv), Non-Stimulant ADHD Medications

October 6, 2024
Jason Mallo, DO and Greg Malzberg, MD
In this video, we explore the use of alpha-2 agonists in the treatment of ADHD, specifically focusing on guanfacine ER (Intuniv) and clonidine ER (Kapvay). These non-stimulant ADHD medications have become viable options for patients who may not tolerate stimulants or have comorbid conditions that make stimulant medications less effective or problematic.
Read More
What You Need to Know About Gepirone (Exxua) _ Benefits, Side Effects, and Review of Trials_Thumb.jpg

What You Need to Know About Gepirone (Exxua) | Benefits, Side Effects, and Review of Trials

September 27, 2024
Chris Aiken, MD. and Greg Malzberg, MD
In this video, Dr. Chris Aiken, Editor-in-Chief of The Carlat Psychiatry Report, provides a comprehensive review of Gepirone, also known as Exxua, a newly FDA-approved antidepressant for major depressive disorder in adults. Gepirone is unique due to its classification as an azipirone, a class of medications that work as serotonin 5-HT1A receptor agonists. 
Read More
CarlatPsychEp1.png
CARLAT WEBINAR

Carlat Psychiatry News - Stimulant Fraud • Oral Ketamine • E-Cigarettes • Benzo Tapering • CBD

September 17, 2024
Chris Aiken, MD, Greg Malzberg, MD, and Kellie Newsome, PMHNP

0.25 CME Credits. In this episode, we explore nine groundbreaking stories in mental health and psychiatric medicine, covering everything from healthcare fraud to the latest advancements in drug trials. First, we dive into the recent charges brought by the US Department of Justice against executives at Done, a California-based telehealth company, for alleged healthcare fraud. Done is accused of prescribing over 40 million Adderall pills to patients without proper evaluation, raising concerns about the balance between increasing mental healthcare access and responsible prescribing practices.


Read More
Depression_Augmention_Thumnail.jpg

Personalized Antidepressant Treatments: Augmentation Options for Different Depression Subtypes

August 25, 2024
Deepti Anbarasan, MD., David Liebers, MD, and Greg Malzberg, MD
In this video, we explore the latest breakthroughs in antidepressant augmentation, showing how personalized medicine can enhance outcomes for patients with various forms of depression. Whether your patient is facing anxious depression, depression with insomnia, or psychotic depression, this video offers evidence-based strategies that incorporate augmenation options such as lithium for depression, esketamine for depression, and quetiapine for depression.
Read More
Vilazodone Review Medication Guide.jpg

Vilazodone Review | Mechanism • Faster Onset? • Better for Anxiety? • Sexual Side-effects?

August 14, 2024
Chris Aiken, MD. and Greg Malzberg, MD
Vilazodone, also known by its brand name Viibryd, became available as a generic in June 2022 after 11 years of market exclusivity. With the introduction of the Viibryd generic, the price of this multimodal antidepressant has significantly decreased, making it more accessible. However, the critical question remains: is vilazodone worth prescribing?
Read More
Carlat Total Access Subscriptions: Get access to every article on the website.

Complete access to every article you search on the website.

Shop for Total Access
Free Psychiatry Updates
The latest unbiased psychiatric information sent to your inbox.
Specify Your Interests
Featured Book
Featured Video
Featured Podcast
Recommended

About

Shop Online

Newsletters

Contact

carlat@thecarlatreport.com

866-348-9279

PO Box 626, Newburyport MA 01950

Follow Us

Please see our Terms and Conditions, Privacy Policy, Subscription Agreement, Use of Cookies, and Hardware/Software Requirements to view our website.

© 2025 Carlat Publishing, LLC and Affiliates, All Rights Reserved.